SIM
KPTI icon

Strategic Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

Strategic Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-706
Closed -$288K – 115
2015
Q2 		$288K Buy
+706
New +$305K 0.19% 56

Other funds holding KPTI

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Strategic Investment Management's KPTI Position: Q3 2015 in Review

Strategic Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2015, closing a stake of 706 shares — an estimated $288K sold.

Strategic Investment Management first reported a position in KPTI in Q2 2015 and held it in 1 quarter. The position peaked at $288K in Q2 2015. 89 funds tracked by Wall St. Rank hold KPTI as of Q3 2015.

  • Strategic Investment Management reported no remaining Karyopharm Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Strategic Investment Management sold 706 Karyopharm Therapeutics shares in Q3 2015, an estimated $288K.
  • Strategic Investment Management first reported a position in Karyopharm Therapeutics in Q2 2015 and held it in 1 quarter.
  • Strategic Investment Management's Karyopharm Therapeutics position peaked at $288K in Q2 2015.
  • 89 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2015.

Based on Strategic Investment Management's 13F filing for Q3 2015, filed 13 Nov 2015.